A research team led by Professor Klaus Gerwert at Ruhr University Bochum has developed a blood test designed to detect Alzheimer's and Parkinson's disease before clinical symptoms emerge. The test relies on what the researchers call an immuno-infrared sensor, a new platform technology that the Journal of Physical Chemistry B features as the cover story of its April 24, 2026 issue.
The timing matters because the treatment landscape has shifted. Therapeutically effective medications for Alzheimer's are now available for the first time, and effective symptomatic therapies exist for Parkinson's. Both depend on catching the disease early - ideally through a straightforward blood draw during routine preventive screening rather than after memory or movement problems have already surfaced.
That gap between damage and diagnosis is the core problem the Bochum group is targeting. Current diagnostic practice is largely symptom-driven, which means a diagnosis typically arrives once the brain has already sustained massive and irreversible damage. A test that works ahead of symptoms would move the intervention window earlier, when treatment has more to protect.
With Alzheimer's and Parkinson's cases climbing sharply in aging populations, the pressure on families and health systems is growing alongside them. A blood-based screening tool of this kind would be far easier to deploy at scale than imaging or spinal fluid testing, though the sensor's path from a journal cover story to routine clinical use still lies ahead.